Document_And_Entity_Informatio
Document And Entity Information | 6 Months Ended | |
Jun. 30, 2014 | Aug. 08, 2014 | |
Document and Entity Information [Abstract] | ' | ' |
Entity Registrant Name | 'Medizone International Inc | ' |
Document Type | '10-Q | ' |
Current Fiscal Year End Date | '--12-31 | ' |
Entity Common Stock, Shares Outstanding | ' | 338,105,496 |
Amendment Flag | 'false | ' |
Entity Central Index Key | '0000753772 | ' |
Entity Current Reporting Status | 'Yes | ' |
Entity Voluntary Filers | 'No | ' |
Entity Filer Category | 'Smaller Reporting Company | ' |
Entity Well-known Seasoned Issuer | 'No | ' |
Document Period End Date | 30-Jun-14 | ' |
Document Fiscal Year Focus | '2014 | ' |
Document Fiscal Period Focus | 'Q2 | ' |
Condensed_Consolidated_Balance
Condensed Consolidated Balance Sheets (Unaudited) (USD $) | Jun. 30, 2014 | Dec. 31, 2013 |
Current Assets: | ' | ' |
Cash | $370,891 | $81,856 |
Inventory | 265,234 | 265,234 |
Prepaid expenses | 35,377 | 33,085 |
Total Current Assets | 671,502 | 380,175 |
Property and equipment, net | 1,090 | 1,616 |
Other Assets: | ' | ' |
Trademark and patents, net | 214,178 | 219,563 |
Lease deposit | 4,272 | 4,272 |
Total Other Assets | 218,450 | 223,835 |
Total Assets | 891,042 | 605,626 |
Current Liabilities: | ' | ' |
Accounts payable | 440,885 | 477,563 |
Accounts payable – related parties | 234,268 | 234,677 |
Accrued expenses | 528,006 | 522,179 |
Accrued expenses – related parties | 1,928,659 | 1,928,659 |
Customer deposits | 30,000 | 30,000 |
Other payables | 224,852 | 224,852 |
Notes payable | 292,845 | 295,496 |
Total Current Liabilities | 3,679,515 | 3,713,426 |
Commitments and Contingencies (Note 5) | ' | ' |
Stockholders’ Deficit: | ' | ' |
Preferred stock, $0.00001 par value: 50,000,000 shares authorized; no shares issued or outstanding | 0 | 0 |
Common stock, $0.001 par value; 395,000,000 shares authorized; 338,105,496 and 322,055,496 shares outstanding, respectively | 338,105 | 322,055 |
Additional paid-in capital | 29,306,825 | 28,018,398 |
Accumulated other comprehensive loss | -23,851 | -26,269 |
Accumulated deficit | -32,409,552 | -31,421,984 |
Total Stockholders' Deficit | -2,788,473 | -3,107,800 |
Total Liabilities and Stockholders’ Deficit | $891,042 | $605,626 |
Condensed_Consolidated_Balance1
Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) (USD $) | Jun. 30, 2014 | Dec. 31, 2013 |
Preferred stock, shares authorized | 50,000,000 | 50,000,000 |
Preferred stock, par value (in Dollars per share) | $0.00 | $0.00 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, shares authorized | 395,000,000 | 395,000,000 |
Common stock, par value (in Dollars per share) | $0.00 | $0.00 |
Common stock, shares outstanding | 338,105,496 | 322,055,496 |
Condensed_Consolidated_Stateme
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (USD $) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2014 | Jun. 30, 2013 | Jun. 30, 2014 | Jun. 30, 2013 | |
Revenues | $0 | $375,000 | $0 | $379,554 |
Operating Expenses: | ' | ' | ' | ' |
Cost of revenues | 0 | 235,436 | 0 | 239,436 |
General and administrative | 445,004 | 308,068 | 734,535 | 593,279 |
Research and development | 129,422 | 34,111 | 216,493 | 119,882 |
Depreciation and amortization | 12,177 | 15,903 | 24,082 | 26,407 |
Total Operating Expenses | 586,603 | 593,518 | 975,110 | 979,004 |
Loss from Operations | -586,603 | -218,518 | -975,110 | -599,450 |
Interest expense | -6,083 | -6,389 | -12,459 | -12,755 |
Net Loss | -592,686 | -224,907 | -987,569 | -612,205 |
Other comprehensive gain (loss) on foreign currency translation | 1,904 | -1,196 | 2,418 | -1,368 |
Total Comprehensive Loss | ($590,782) | ($226,103) | ($985,151) | ($613,573) |
Basic and Diluted Net Loss per Common Share (in Dollars per share) | $0 | $0 | $0 | $0 |
Weighted Average Number of Common Shares Outstanding (in Shares) | 338,105,496 | 305,341,194 | 331,129,640 | 300,432,370 |
Condensed_Consolidated_Stateme1
Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $) | 6 Months Ended | |
Jun. 30, 2014 | Jun. 30, 2013 | |
Cash Flows from Operating Activities: | ' | ' |
Net loss | ($987,569) | ($612,205) |
Adjustments to reconcile net loss to net cash used in operating activities: | ' | ' |
Depreciation and amortization | 24,082 | 26,219 |
Stock-based compensation | 255,227 | 94,707 |
Changes in operating assets and liabilities: | ' | ' |
Prepaid expenses | 24,877 | -123,883 |
Inventory | 0 | 45,548 |
Accounts payable and accounts payable – related parties | -37,087 | 101,708 |
Accrued expenses and accrued expenses – related parties | 5,827 | -25,315 |
Customer deposits | 0 | -4,554 |
Net Cash Used in Operating Activities | -714,643 | -497,775 |
Cash Flows from Investing Activities: | ' | ' |
Purchase of trademark and patents | -18,170 | -12,954 |
Purchase of property and equipment | 0 | -7,540 |
Net Cash Used in Investing Activities | -18,170 | -20,494 |
Cash Flows from Financing Activities: | ' | ' |
Principal payments on notes payable | -29,820 | -32,790 |
Issuance of common stock for cash | 1,049,250 | 860,250 |
Net Cash Provided by Financing Activities | 1,019,430 | 827,460 |
Effect of Foreign Currency Exchange Rates | 2,418 | -1,368 |
Net increase in cash | 289,035 | 307,823 |
Cash as of beginning of the period | 81,856 | 12,456 |
Cash as of end of the period | 370,891 | 320,279 |
SUPPLEMENTAL CASH FLOW INFORMATION: | ' | ' |
Cash paid for interest | 631 | 537 |
NON-CASH FINANCING ACTIVITIES: | ' | ' |
Financing of insurance policies | $27,169 | $27,250 |
NOTE_1_BASIS_OF_PRESENTATION
NOTE 1 BASIS OF PRESENTATION | 6 Months Ended |
Jun. 30, 2014 | |
Disclosure Text Block [Abstract] | ' |
Business Description and Basis of Presentation [Text Block] | ' |
NOTE 1 BASIS OF PRESENTATION | |
The financial information included herein is unaudited and has been prepared consistent with U.S. generally accepted accounting principles (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all information and notes required by US GAAP for complete financial statements. These notes should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2013. In the opinion of management, these financial statements contain all adjustments (consisting solely of normal recurring adjustments) which are, in the opinion of management, necessary for a fair presentation of results for the interim periods presented. The results of operations for the three and six-month periods ended June 30, 2014 are not necessarily indicative of the results to be expected for the full year. | |
NOTE_2_CANADIAN_FOUNDATION_FOR
NOTE 2 CANADIAN FOUNDATION FOR GLOBAL HEALTH | 6 Months Ended |
Jun. 30, 2014 | |
Disclosure Text Block [Abstract] | ' |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | ' |
NOTE 2 CANADIAN FOUNDATION FOR GLOBAL HEALTH | |
In late 2008, the Company assisted in the formation of the Canadian Foundation for Global Health (“CFGH”), a not-for-profit foundation based in Ottawa, Canada. The Company helped establish CFGH for two primary purposes: (1) to establish an independent not-for-profit foundation intended to have a continuing working relationship with the Company for research purposes that is best positioned to attract the finest scientific, medical and academic professionals possible to work on projects deemed to be of social benefit; and (2) to provide a means for the Company to use a tiered pricing structure for services and products in emerging economies and extend the reach of the Company’s technology to as many in need as possible. | |
Accounting standards require a variable interest entity (“VIE”) to be consolidated by a company if that company absorbs a majority of the VIE’s expected losses and/or receives a majority of the entity’s expected residual returns as a result of holding variable interests, which are the ownership, contractual, or other financial interests in the entity. In addition, a legal entity may be considered to be a VIE, if it does not have sufficient equity at risk to finance its own activities without relying on financial support from other parties. If the legal entity is a VIE, then the reporting entity determined to be the primary beneficiary of the VIE must consolidate its financial statements with those of the VIE. The Company determined that CFGH met the requirements of a VIE effective upon the first advance to CFGH on February 12, 2009. Accordingly, the financial statements of CFGH have been consolidated with those of the Company for all periods presented. | |
NOTE_3_BASIC_AND_DILUTED_NET_L
NOTE 3 BASIC AND DILUTED NET LOSS PER COMMON SHARE | 6 Months Ended | ||||||||
Jun. 30, 2014 | |||||||||
Earnings Per Share [Abstract] | ' | ||||||||
Earnings Per Share [Text Block] | ' | ||||||||
NOTE 3 BASIC AND DILUTED NET LOSS PER COMMON SHARE | |||||||||
The computations of basic and diluted net loss per common share are based on the weighted average number of common shares outstanding during the periods as follows: | |||||||||
For the Three Months Ended | |||||||||
June 30, | |||||||||
2014 | 2013 | ||||||||
Numerator: Net loss | $ | (592,686 | ) | $ | (224,907 | ) | |||
Denominator: Weighted average number of common shares outstanding | 338,105,496 | 305,341,194 | |||||||
Basic and diluted net loss per common share | $ | (0.00 | ) | $ | (0.00 | ) | |||
For the Six Months Ended | |||||||||
June 30, | |||||||||
2014 | 2013 | ||||||||
Numerator: Net loss | $ | (987,569 | ) | $ | (612,205 | ) | |||
Denominator: Weighted average number of common shares outstanding | 331,129,640 | 300,432,370 | |||||||
Basic and diluted net loss per common share | $ | (0.00 | ) | $ | (0.00 | ) | |||
Common stock equivalents, consisting of options, have not been included in the calculation as their effect is antidilutive for the periods presented. | |||||||||
NOTE_4_GOING_CONCERN
NOTE 4 GOING CONCERN | 6 Months Ended |
Jun. 30, 2014 | |
Going Concern Disclosure [Abstract] | ' |
Going Concern Disclosure [Text Block] | ' |
NOTE 4 GOING CONCERN | |
The Company’s consolidated financial statements are prepared using US GAAP applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has incurred significant losses from its inception through June 30, 2014, which have resulted in an accumulated deficit of $32,409,552 as of June 30, 2014. The Company does not have funds sufficient to cover its operating costs for the next 12 months, has a working capital deficit of $3,008,013, and has relied exclusively on debt and equity financing. Accordingly, there is substantial doubt about its ability to continue as a going concern. | |
Continuation of the Company as a going concern is dependent upon future revenues, obtaining additional capital and ultimately, upon the Company’s attaining profitable operations. The Company will require substantial additional funds to complete the continued development of its products, product manufacturing, and to fund expected additional losses, until revenues are sufficient to cover the Company’s operating expenses. If the Company is unsuccessful in obtaining the necessary additional funding, it will be forced to substantially reduce or cease operations. | |
The Company believes that it will need approximately $1,500,000 over the next 12 months for continued production manufacturing, research, development, and marketing activities, as well as for general corporate purposes. | |
During 2013, the Company raised a total of $1,413,250 through the sale of 33,284,269 shares of common stock at prices ranging from $0.03 to $0.06 per share, which funds have been used to keep the Company current in its public reporting obligations and to pay certain other corporate obligations including the costs of development for its hospital disinfection system. During the six months ended June 30, 2014, the Company raised a total of $1,049,250 through the sale of 16,050,000 shares of common stock at prices ranging from $0.05 to $0.085 per share. The Company believes it will be able to raise additional funds from some of the same investors who have purchased shares from 2009 to 2014, although there is no assurance that these investors will purchase additional shares. | |
The ability of the Company to continue as a going concern is dependent on its ability to successfully accomplish the plan described in the preceding paragraphs and eventually attain profitable operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this uncertainty. | |
NOTE_5_COMMITMENTS_AND_CONTING
NOTE 5 COMMITMENTS AND CONTINGENCIES | 6 Months Ended |
Jun. 30, 2014 | |
Commitments and Contingencies Disclosure [Abstract] | ' |
Commitments and Contingencies Disclosure [Text Block] | ' |
NOTE 5 COMMITMENTS AND CONTINGENCIES | |
The Company is subject to certain claims and lawsuits arising in the normal course of business. In the opinion of management, uninsured losses, if any, resulting from the ultimate resolution of these matters, will not have a material effect on the Company’s consolidated financial position, results of operations, or cash flows. | |
Litigation | |
Rakas vs. Medizone International, Inc. - A former consultant brought this action against the Company claiming the Company had failed to pay consulting fees under a consulting agreement. In September 2001, the parties agreed to settle the matter for $25,000. The Company, however, did not have the funds to pay the settlement and the plaintiff moved the court to enter a default judgment in the amount of $143,000 in January 2002. On May 8, 2002, the court vacated the default judgment and requested that the Company post a bond of $25,000 to cover the settlement previously entered into by the parties. The Company has been unable to post the required bond amount as of the date of this report. Therefore, the Company has recorded, as part of accounts payable, the original default judgment in the amount of $143,000, plus fees totaling $21,308, as of June 30, 2014 and December 31, 2013. The Company intends to contest the judgment if and when it is able to in the future. | |
Other Payables | |
As of June 30, 2014 and December 31, 2013, the Company has $224,852 of past due payables for which the Company has not received invoices or demands for over 10 years. Although management of the Company does not believe that the amounts will be required to be paid, the amounts are recorded as other payables until such time as the Company is certain that no liability exists and until the statute of limitations has expired. | |
Operating Leases | |
The Company operates a certified laboratory located at Innovation Park, Queen’s University in Kingston, Ontario, Canada, which provides a primary research and development platform. The lease term is month–to-month with a monthly lease payment of $1,375 Canadian dollars (“CD”) plus the applicable goods and services tax (“GST”). Leases for a second laboratory space for full scale room testing and a storage unit are on a month-to-month basis with a monthly lease payment of CD$1,375 and CD$475, respectively, plus the applicable GST. | |
The Company has a corporate office lease arrangement in Sausalito, California with monthly payments of $2,300 through December 31, 2014. | |
NOTE_6_COMMON_STOCK_OPTIONS
NOTE 6 COMMON STOCK OPTIONS | 6 Months Ended | ||||||||
Jun. 30, 2014 | |||||||||
Disclosure Text Block Supplement [Abstract] | ' | ||||||||
Shareholders' Equity and Share-based Payments [Text Block] | ' | ||||||||
NOTE 6 COMMON STOCK OPTIONS | |||||||||
On August 26, 2009, the Company granted options for the purchase of 1,500,000 shares of common stock to an outside consultant for services rendered, with an exercise price of $0.10 per share, exercisable for up to five years, but including vesting provisions as follows: (i) options for 500,000 shares vested immediately on the date of grant, (ii) options for 500,000 additional shares vested in September 2012, the date certified by the Company as the date the Company’s hospital disinfection program completed its beta-testing, and (iii) options for the remaining 500,000 shares will vest on the date certified by the Company as the date that the Company’s process has been commercialized and a minimum of 50 units or devices have been sold to third parties by the Company. As of June 30, 2014, 500,000 shares had not yet vested and represent a deferred expense of $48,698. | |||||||||
In May 2012, the Company granted options for the purchase of 1,000,000 shares of common stock to an individual for services. Options for 550,000 shares have vested and the remaining options will vest on the date certified by the Company as the date that certain milestones are achieved. The options have an exercise price of $0.17 per share, and are exercisable for up to five years. The value of these options at the date of grant was $153,997, in connection with which the Company recognized $0 and $69,298 during the six months ended June 30, 2014 and 2013, respectively. The Company will recognize the remaining expense, totaling $69,300, when the achievement of the required milestones becomes probable. | |||||||||
In May 2012, the Company granted options for the purchase of 1,000,000 shares of common stock to an individual for medical consulting support services already performed. Options for 500,000 shares vested immediately on the grant date and 500,000 shares vested upon completion of certain milestones as of March 31, 2013 and September 30, 2013. The options have an exercise price of $0.17 per share and are exercisable for up to five years. The grant date fair value of these options was $149,460, in connection with which the Company recognized $25,409 during the six months ended June 30, 2013 and the final $23,913 during the three months ended September 30, 2013. | |||||||||
In August 2013, the Company granted options for the purchase of 250,000 shares of common stock to a consultant. These options are exercisable at $0.10 per share for five years from the date of grant. Options for 50,000 shares vested immediately and options for the remaining 200,000 shares will vest upon the achievement of certain milestones. The value of these options on the date of grant was $22,075, of which the Company recognized $4,416 during the three months ended September 30, 2013. As of June 30, 2014, options for 200,000 shares had not yet vested and represent deferred expense of $17,659 to be recognized when the achievement of the required milestones becomes probable. | |||||||||
In August 2013, the Company granted options for the purchase of 100,000 shares of common stock to an employee for services performed. The options vested upon grant, have an exercise price of $0.10 per share, and are exercisable for up to five years. The value of the options at the date of grant was $8,829, which the Company recognized as an expense during the three months ended September 30, 2013. | |||||||||
On February 26, 2014, the Company granted to a new director options for the purchase of 2,000,000 shares of common stock, with an exercise price of $0.1095 per share. Of these options, 1,000,000 will vest on February 26, 2015 and the remaining 1,000,000 options will vest upon the successful achievement of certain milestones. Unvested options would vest immediately in the event of a change in control of the Company. The options are exercisable for five years. The grant date fair value of the options was $192,184. The Company recognized $32,030 of expense during the six months ended June 30, 2014, with $64,062 to be recognized over the remaining vesting period in connection with those options that vest on February 26, 2015. Also, the Company will recognize an expense totaling $96,092 when the achievement of the required milestones becomes probable. | |||||||||
On February 26, 2014, the Company granted options to six consultants and service providers for the purchase of a total of 250,000 shares of common stock at an exercise price of $0.1095 per share. Options for 200,000 shares vested immediately upon grant and options for the remaining 50,000 shares will vest on January 9, 2015. The options are exercisable for five years. The grant date fair value of these options was $24,023. The Company recognized expense of $21,621 during the six months ended June 30, 2014 and the remaining expense of $2,402 will be recognized over the remaining vesting period in connection with those options that vest on January 9, 2015. | |||||||||
On April 30, 2014, the Company granted options for the purchase of a total of 1,350,000 shares of common stock for services rendered, as follows: 250,000 shares to each of four directors of the Company, 100,000 shares to each of two consultants, and 75,000 shares each to a consultant and an employee of the Company. All options vested upon grant, have an exercise price of $0.163 per share, and are exercisable for up to five years. The total value of these options at the date of grant was $193,234, which the Company recognized as an expense during the three months ended June 30, 2014. | |||||||||
On May 6, 2014, the Company granted options to a consultant for the purchase of 100,000 shares of common stock at an exercise price of $0.19 per share. Options for 50,000 shares vested immediately upon grant and options for the remaining 50,000 shares will vest when certain required milestones are achieved. The options are exercisable for five years. The grant date fair value of these options was $16,684. The Company recognized expense of $8,342 during the three months ended June 30, 2014 and the remaining expense of $8,342 will be recognized when the achievement of the required milestones becomes probable. | |||||||||
The options granted in April and May were made under the Company’s new 2014 Equity Compensation Plan (the 2014 Plan) adopted on April 30, 2014 by the Board of Directors. The Company filed a registration statement on Form S-8 on July 17, 2014, to register 6,000,000 shares of common stock that may be issued under the 2014 Plan. | |||||||||
The Company estimated the fair value of the stock options described in the above paragraphs at the date of the grant, based on the following weighted average assumptions: | |||||||||
Risk-free interest rate | 1.69 | % | |||||||
Expected life | 5 years | ||||||||
Expected volatility | 136.44 | % | |||||||
Dividend yield | 0 | % | |||||||
A summary of the status of the Company’s outstanding options as of June 30, 2014 and for the six months then ended, is presented below: | |||||||||
Shares | Weighted Average Exercise Price | ||||||||
Outstanding, beginning of the period | 15,150,000 | $ | 0.19 | ||||||
Granted | 3,700,000 | 0.131 | |||||||
Expired/Canceled | - | - | |||||||
Exercised | - | - | |||||||
Outstanding, end of the period | 18,850,000 | 0.123 | |||||||
Exercisable | 15,600,000 | 0.131 | |||||||
The Company estimates the fair value of each stock option award by using the Black-Scholes option-pricing model, which model requires the use of exercise behavior data and the use of a number of assumptions including volatility of the Company’s stock price, the weighted average risk-free interest rate, and the weighted average expected life of the options. Because the Company does not pay dividends, the dividend rate variable in the Black-Scholes option-pricing model is zero. Expense of $255,227 and $94,707 related to stock options was recorded for the six-months ended June 30, 2014 and 2013, respectively. As of June 30, 2014, the Company had various unvested outstanding options with related unrecognized expense of $306,555. The Company will recognize this expense as these options vest over their remaining useful lives, which range from 5 to 59 months. | |||||||||
NOTE_7_STOCK_TRANSACTIONS_AND_
NOTE 7 STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS | 6 Months Ended |
Jun. 30, 2014 | |
Stockholders' Equity Note [Abstract] | ' |
Stockholders' Equity Note Disclosure [Text Block] | ' |
NOTE 7 STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS | |
During January, February and March 2014, the Company sold an aggregate of 9,000,000 restricted shares of common stock to six accredited investors for cash proceeds totaling $450,000, or $0.05 per share. | |
During March 2014, the Company sold an aggregate of 7,050,000 restricted shares of common stock to 16 accredited investors for cash proceeds totaling $599,250, or $0.085 per share. | |
During January, February, and March 2013, the Company sold an aggregate of 12,233,332 restricted shares of common stock to 12 accredited investors for cash proceeds totaling $367,000, or $0.03 per share. | |
During April and May 2013, the Company sold 3,794,444 restricted shares of common stock to six accredited investors for cash proceeds totaling $170,750, or $0.045 per share. | |
During May and June 2013, the Company sold 5,863,636 restricted shares of common stock to 11 accredited investors for cash proceeds totaling $322,500, or $0.055 per share. | |
NOTE_8_ACCOUNTS_PAYABLE_RELATE
NOTE 8 ACCOUNTS PAYABLE - RELATED PARTIES | 6 Months Ended |
Jun. 30, 2014 | |
Related Party Transactions [Abstract] | ' |
Related Party Transactions Disclosure [Text Block] | ' |
NOTE 8 ACCOUNTS PAYABLE – RELATED PARTIES | |
As of June 30, 2014 and December 31, 2013, the Company had accounts payable of $234,268 and $234,677, respectively, owed to certain consultants for services rendered in prior years. These consultants are stockholders of the Company. | |
NOTE_9_RECENT_ACCOUNTING_PRONO
NOTE 9 RECENT ACCOUNTING PRONOUNCEMENTS | 6 Months Ended |
Jun. 30, 2014 | |
New Accounting Pronouncements and Changes in Accounting Principles [Abstract] | ' |
New Accounting Pronouncements and Changes in Accounting Principles [Text Block] | ' |
NOTE 9 RECENT ACCOUNTING PRONOUNCEMENTS | |
In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606), (“ASU 2014-09”). ASU 2014-09 is a comprehensive new revenue recognition model requiring a company to recognize revenue to depict the transfer of goods or services to a customer at an amount reflecting the consideration it expects to receive in exchange for those goods or services. In adopting ASU 2014-09, companies may use either a full retrospective or a modified retrospective approach. ASU 2014-09 is effective for the first interim period within annual reporting periods beginning after December 15, 2016, and early adoption is no permitted. The Company will adopt ASU 2014-09 during the first quarter of fiscal 2017. Management is evaluating the provisions of this update and has not determined what impact its adoption will have on the Company’s financial position or results of operations. | |
NOTE_3_BASIC_AND_DILUTED_NET_L1
NOTE 3 BASIC AND DILUTED NET LOSS PER COMMON SHARE (Tables) | 6 Months Ended | ||||||||
Jun. 30, 2014 | |||||||||
Earnings Per Share [Abstract] | ' | ||||||||
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | 'The computations of basic and diluted net loss per common share are based on the weighted average number of common shares outstanding during the periods as follows: | ||||||||
For the Three Months Ended | |||||||||
June 30, | |||||||||
2014 | 2013 | ||||||||
Numerator: Net loss | $ | (592,686 | ) | $ | (224,907 | ) | |||
Denominator: Weighted average number of common shares outstanding | 338,105,496 | 305,341,194 | |||||||
Basic and diluted net loss per common share | $ | (0.00 | ) | $ | (0.00 | ) | |||
For the Six Months Ended | |||||||||
June 30, | |||||||||
2014 | 2013 | ||||||||
Numerator: Net loss | $ | (987,569 | ) | $ | (612,205 | ) | |||
Denominator: Weighted average number of common shares outstanding | 331,129,640 | 300,432,370 | |||||||
Basic and diluted net loss per common share | $ | (0.00 | ) | $ | (0.00 | ) |
NOTE_6_COMMON_STOCK_OPTIONS_Ta
NOTE 6 COMMON STOCK OPTIONS (Tables) | 6 Months Ended | ||||||||
Jun. 30, 2014 | |||||||||
Disclosure Text Block Supplement [Abstract] | ' | ||||||||
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | 'The Company estimated the fair value of the stock options described in the above paragraphs at the date of the grant, based on the following weighted average assumptions: | ||||||||
Risk-free interest rate | 1.69 | % | |||||||
Expected life | 5 years | ||||||||
Expected volatility | 136.44 | % | |||||||
Dividend yield | 0 | % | |||||||
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] | 'A summary of the status of the Company’s outstanding options as of June 30, 2014 and for the six months then ended, is presented below: | ||||||||
Shares | Weighted Average Exercise Price | ||||||||
Outstanding, beginning of the period | 15,150,000 | $ | 0.19 | ||||||
Granted | 3,700,000 | 0.131 | |||||||
Expired/Canceled | - | - | |||||||
Exercised | - | - | |||||||
Outstanding, end of the period | 18,850,000 | 0.123 | |||||||
Exercisable | 15,600,000 | 0.131 |
NOTE_2_CANADIAN_FOUNDATION_FOR1
NOTE 2 CANADIAN FOUNDATION FOR GLOBAL HEALTH (Details) | 12 Months Ended |
Dec. 31, 2008 | |
Disclosure Text Block [Abstract] | ' |
Variable Interest Entity, Qualitative or Quantitative Information, Purpose of VIE | '(1) to establish an independent not-for-profit foundation intended to have a continuing working relationship with the Company for research purposes that is best positioned to attract the finest scientific, medical and academic professionals possible to work on projects deemed to be of social benefit; and (2) to provide a means for the Company to use a tiered pricing structure for services and products in emerging economies and extend the reach of the Company's technology to as many in need as possible. |
NOTE_3_BASIC_AND_DILUTED_NET_L2
NOTE 3 BASIC AND DILUTED NET LOSS PER COMMON SHARE (Details) - Schedule of Earnings Per Share, Basic and Diluted (USD $) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2014 | Jun. 30, 2013 | Jun. 30, 2014 | Jun. 30, 2013 | |
Schedule of Earnings Per Share, Basic and Diluted [Abstract] | ' | ' | ' | ' |
Numerator: Net loss | ($592,686) | ($224,907) | ($987,569) | ($612,205) |
Denominator: Weighted average number of common shares outstanding | 338,105,496 | 305,341,194 | 331,129,640 | 300,432,370 |
Basic and diluted net loss per common share | $0 | $0 | $0 | $0 |
NOTE_4_GOING_CONCERN_Details
NOTE 4 GOING CONCERN (Details) (USD $) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2014 | Dec. 31, 2013 | |
NOTE 4 GOING CONCERN (Details) [Line Items] | ' | ' |
Retained Earnings (Accumulated Deficit) | ($32,409,552) | ($31,421,984) |
Working Capital (Deficit) | -3,008,013 | ' |
Going Concern Note | 'The Company believes that it will need approximately $1,500,000 over the next 12 months for continued production manufacturing, research, development, and marketing activities, as well as for general corporate purposes. | ' |
Proceeds from Issuance of Common Stock | $1,049,250 | $1,413,250 |
Stock Issued During Period, Shares, New Issues | 16,050,000 | 33,284,269 |
Minimum [Member] | ' | ' |
NOTE 4 GOING CONCERN (Details) [Line Items] | ' | ' |
Sale of Stock, Price Per Share | $0.05 | $0.03 |
Maximum [Member] | ' | ' |
NOTE 4 GOING CONCERN (Details) [Line Items] | ' | ' |
Sale of Stock, Price Per Share | $0.09 | $0.06 |
NOTE_5_COMMITMENTS_AND_CONTING1
NOTE 5 COMMITMENTS AND CONTINGENCIES (Details) | Jun. 30, 2014 | Dec. 31, 2013 | Jun. 30, 2014 | Jun. 30, 2014 | Jun. 30, 2014 | Jun. 30, 2014 | Jun. 30, 2014 | Dec. 31, 2013 | 8-May-02 | Jan. 31, 2002 | Sep. 30, 2001 | Jun. 30, 2014 | Dec. 31, 2013 |
USD ($) | USD ($) | Certified Laboratory [Member] | Second Laboratory Space [Member] | Storage Unit [Member] | Building [Member] | Rakas Litigation [Member] | Rakas Litigation [Member] | Rakas Litigation [Member] | Rakas Litigation [Member] | Rakas Litigation [Member] | Rakas Litigation [Member] | Rakas Litigation [Member] | |
CAD | CAD | CAD | USD ($) | Litigation Fees [Member] | Litigation Fees [Member] | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |||
USD ($) | USD ($) | ||||||||||||
NOTE 5 COMMITMENTS AND CONTINGENCIES (Details) [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Litigation Settlement, Amount | ' | ' | ' | ' | ' | ' | ' | ' | $25,000 | ' | $25,000 | ' | ' |
Loss Contingency, Damages Sought, Value | ' | ' | ' | ' | ' | ' | ' | ' | ' | 143,000 | ' | ' | ' |
Accounts Payable, Current | 440,885 | 477,563 | ' | ' | ' | ' | 21,308 | 21,308 | ' | ' | ' | 143,000 | 143,000 |
Accounts Payable, Other, Current | 224,852 | 224,852 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Operating Leases, Rent Expense, Minimum Rentals | ' | ' | 1,375 | 1,375 | 475 | $2,300 | ' | ' | ' | ' | ' | ' | ' |
NOTE_6_COMMON_STOCK_OPTIONS_De
NOTE 6 COMMON STOCK OPTIONS (Details) (USD $) | 0 Months Ended | 6 Months Ended | 0 Months Ended | 0 Months Ended | 0 Months Ended | 6 Months Ended | 6 Months Ended | 0 Months Ended | 1 Months Ended | 0 Months Ended | 1 Months Ended | 0 Months Ended | 1 Months Ended | 3 Months Ended | 1 Months Ended | 6 Months Ended | 1 Months Ended | 3 Months Ended | 6 Months Ended | 1 Months Ended | 3 Months Ended | 0 Months Ended | 3 Months Ended | 6 Months Ended | ||||||||||||||||||||||||||||||
Apr. 30, 2014 | Jun. 30, 2014 | Jun. 30, 2013 | Feb. 26, 2014 | Jun. 30, 2014 | Feb. 26, 2014 | Jun. 30, 2014 | Feb. 26, 2014 | Jun. 30, 2014 | Feb. 26, 2014 | Jun. 30, 2014 | Jun. 30, 2014 | Jun. 30, 2014 | Jun. 30, 2014 | 6-May-14 | Feb. 26, 2014 | Aug. 26, 2009 | Aug. 31, 2013 | 31-May-12 | 31-May-12 | 6-May-14 | Feb. 26, 2014 | Aug. 26, 2009 | Aug. 31, 2013 | 31-May-12 | 31-May-12 | Aug. 26, 2009 | 6-May-14 | Apr. 30, 2014 | Feb. 26, 2014 | Aug. 26, 2009 | Aug. 31, 2013 | Jun. 30, 2014 | Sep. 30, 2013 | 6-May-14 | Feb. 26, 2014 | 31-May-12 | Jun. 30, 2014 | Jun. 30, 2013 | Mar. 31, 2014 | 31-May-12 | Sep. 30, 2013 | Jun. 30, 2013 | Aug. 31, 2013 | Sep. 30, 2013 | Apr. 30, 2014 | Apr. 30, 2014 | Apr. 30, 2014 | Apr. 30, 2014 | Jun. 30, 2014 | Apr. 30, 2014 | Jun. 30, 2014 | Jun. 30, 2014 | Jun. 30, 2014 | |
Director [Member] | Director [Member] | Director [Member] | Director [Member] | Director [Member] | Director [Member] | Director [Member] | August 26, 2009 [Member] | August 2013 [Member] | February 26, 2014 [Member] | May 6, 2014 [Member] | Share-based Compensation Award, Tranche One [Member] | Share-based Compensation Award, Tranche One [Member] | Share-based Compensation Award, Tranche One [Member] | Share-based Compensation Award, Tranche One [Member] | Share-based Compensation Award, Tranche One [Member] | Share-based Compensation Award, Tranche One [Member] | Share-based Compensation Award, Tranche Two [Member] | Share-based Compensation Award, Tranche Two [Member] | Share-based Compensation Award, Tranche Two [Member] | Share-based Compensation Award, Tranche Two [Member] | Share-based Compensation Award, Tranche Two [Member] | Share-based Compensation Award, Tranche Two [Member] | Share-based Compensation Award, Tranche Three [Member] | Options Granted to Consultant for Services [Member] | Options Granted to Consultant for Services [Member] | Options Granted to Consultant for Services [Member] | Options Granted to Consultant for Services [Member] | Options Granted to Consultant for Services [Member] | Options Granted to Consultant for Services [Member] | Options Granted to Consultant for Services [Member] | Options Granted to Consultant for Services [Member] | Options Granted to Consultant for Services [Member] | Options Granted to Individual for Services [Member] | Options Granted to Individual for Services [Member] | Options Granted to Individual for Services [Member] | Options Granted to Individual for Services [Member] | Options Granted to Medical Consulting Support Services [Member] | Options Granted to Medical Consulting Support Services [Member] | Options Granted to Medical Consulting Support Services [Member] | Options Granted to Employee for Services [Member] | Options Granted to Employee for Services [Member] | Options Granted for Services [Member] | Options Granted for Services [Member] | Options Granted for Services [Member] | Options Granted for Services [Member] | Options Granted for Services [Member] | Options Granted for Services [Member] | 2014 Equity Compensation Plan [Member] | Minimum [Member] | Maximum [Member] | ||||
Share-based Compensation Award, Tranche One [Member] | Share-based Compensation Award, Tranche One [Member] | Share-based Compensation Award, Tranche Two [Member] | Share-based Compensation Award, Tranche Two [Member] | Options Granted to Consultant for Services [Member] | Options Granted to Consultant for Services [Member] | Options Granted to Consultant for Services [Member] | Options Granted to Consultant for Services [Member] | Options Granted to Consultant for Services [Member] | Options Granted to Consultant for Services [Member] | Options Granted to Consultant for Services [Member] | Options Granted to Consultant for Services [Member] | Options Granted to Individual for Services [Member] | Options Granted to Medical Consulting Support Services [Member] | Options Granted to Consultant for Services [Member] | Options Granted to Consultant for Services [Member] | Options Granted to Consultant for Services [Member] | Options Granted to Consultant for Services [Member] | Options Granted to Individual for Services [Member] | Options Granted to Medical Consulting Support Services [Member] | Options Granted to Consultant for Services [Member] | Each Director [Member] | Each Consultant [Member] | Each to a Consultant and an Employee [Member] | |||||||||||||||||||||||||||||||
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | ' | ' | ' | ' | ' | ' | ' | 2,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 100,000 | ' | 250,000 | 1,500,000 | 250,000 | ' | ' | ' | ' | 1,000,000 | ' | ' | ' | 1,000,000 | ' | ' | 100,000 | ' | 250,000 | 100,000 | 75,000 | 1,350,000 | ' | ' | ' | ' | ' |
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share) | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0.11 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0.10 | $0.10 | ' | $0.19 | $0.11 | $0.17 | ' | ' | ' | $0.17 | ' | ' | $0.10 | ' | ' | ' | ' | ' | ' | $0.16 | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | '5 years | ' | ' | ' | ' | ' | ' | '5 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '5 years | ' | '5 years | '5 years | '5 years | ' | ' | ' | ' | '5 years | ' | ' | ' | '5 years | ' | ' | '5 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares | ' | ' | ' | 1,000,000 | ' | 1,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | 50,000 | 200,000 | 500,000 | 50,000 | 550,000 | 500,000 | 50,000 | 50,000 | 500,000 | 200,000 | ' | 500,000 | 500,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights | ' | ' | ' | ' | ' | 'vest upon the successful achievement of certain milestones | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 'vest upon the achievement of certain milestones | 'remaining options will vest on the date certified by the Company as the date that certain milestones are achieved | ' | 'vest on the date certified by the Company as the date that the Company's process has been commercialized and a minimum of 50 units or devices have been sold to third parties by the Company | 'vest when certain required milestones are achieved | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 500,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 200,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars) | ' | $306,555 | ' | ' | $64,062 | ' | $96,092 | ' | ' | ' | $48,698 | $17,659 | $2,402 | $8,342 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $69,300 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount (in Dollars) | ' | ' | ' | ' | ' | ' | ' | 192,184 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 16,684 | 24,023 | ' | 22,075 | ' | ' | ' | ' | 153,997 | ' | ' | ' | 149,460 | ' | ' | 8,829 | ' | ' | ' | ' | 193,234 | ' | ' | ' | ' | ' |
Allocated Share-based Compensation Expense (in Dollars) | ' | $255,227 | $94,707 | ' | ' | ' | ' | ' | $32,030 | ' | ' | ' | $21,621 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $8,342 | $4,416 | ' | ' | ' | $0 | $69,298 | ' | ' | $23,913 | $25,409 | ' | $8,829 | ' | ' | ' | ' | $193,234 | ' | ' | ' | ' |
Number of consultants and service providers issued options | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 6 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of Directors | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4 | ' | ' | ' | ' | ' | ' | ' | ' |
Number of Consultants | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2 | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 6,000,000 | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | ' | 0.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '5 months | '59 months |
NOTE_6_COMMON_STOCK_OPTIONS_De1
NOTE 6 COMMON STOCK OPTIONS (Details) - Schedule of Fair Value Assumptions of Stock Options | 6 Months Ended |
Jun. 30, 2014 | |
NOTE 6 COMMON STOCK OPTIONS (Details) - Schedule of Fair Value Assumptions of Stock Options [Line Items] | ' |
Dividend yield | 0.00% |
Employee Stock Option [Member] | ' |
NOTE 6 COMMON STOCK OPTIONS (Details) - Schedule of Fair Value Assumptions of Stock Options [Line Items] | ' |
Risk-free interest rate | 1.69% |
Expected life | '5 years |
Expected volatility | 136.44% |
Dividend yield | 0.00% |
NOTE_6_COMMON_STOCK_OPTIONS_De2
NOTE 6 COMMON STOCK OPTIONS (Details) - Schedule of Share-Based Compensation, Stock Options, Activity (USD $) | 6 Months Ended |
Jun. 30, 2014 | |
Shares [Member] | ' |
NOTE 6 COMMON STOCK OPTIONS (Details) - Schedule of Share-Based Compensation, Stock Options, Activity [Line Items] | ' |
Outstanding, beginning of the period | 15,150,000 |
Granted | 3,700,000 |
Expired/Canceled | 0 |
Exercised | 0 |
Outstanding, end of the period | 18,850,000 |
Exercisable | 15,600,000 |
Weighted Average Exercise Price [Member] | ' |
NOTE 6 COMMON STOCK OPTIONS (Details) - Schedule of Share-Based Compensation, Stock Options, Activity [Line Items] | ' |
Outstanding, beginning of the period | 0.19 |
Granted | 0.131 |
Expired/Canceled | 0 |
Exercised | 0 |
Outstanding, end of the period | 0.123 |
Exercisable | 0.131 |
NOTE_7_STOCK_TRANSACTIONS_AND_1
NOTE 7 STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS (Details) (USD $) | 6 Months Ended | 12 Months Ended | 3 Months Ended | 1 Months Ended | 2 Months Ended | 3 Months Ended | 14 Months Ended | |
Jun. 30, 2014 | Jun. 30, 2013 | Dec. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2014 | Jun. 30, 2013 | Mar. 31, 2013 | 30-May-14 | |
Restricted Shares Issued for Cash January, February and March 2014 [Member] | Restricted Shares Issued for Cash March 2014 [Member] | Restricted Shares Issued for Cash [Member] | Restricted Shares Issued for Cash [Member] | Restricted Shares Issued for Cash [Member] | ||||
NOTE 7 STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS (Details) [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' |
Stock Issued During Period, Shares, New Issues | 16,050,000 | ' | 33,284,269 | 9,000,000 | 7,050,000 | 5,863,636 | 12,233,332 | 3,794,444 |
Number of Investors | ' | ' | ' | 6 | 16 | 11 | 12 | 6 |
Proceeds from Issuance or Sale of Equity | $1,049,250 | $860,250 | ' | $450,000 | $599,250 | $322,500 | $367,000 | $170,750 |
Shares Issued, Price Per Share | ' | ' | ' | $0.05 | $0.09 | $0.06 | $0.03 | $0.05 |
NOTE_8_ACCOUNTS_PAYABLE_RELATE1
NOTE 8 ACCOUNTS PAYABLE - RELATED PARTIES (Details) (USD $) | Jun. 30, 2014 | Dec. 31, 2013 |
Related Party Transactions [Abstract] | ' | ' |
Accounts Payable, Related Parties, Current | $234,268 | $234,677 |